BETA
Your AI-Trained Oncology Knowledge Connection!
Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC
Phase 2 CRDF-004 results revealed that adding onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.
Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL
Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.
Pushing for Clinical Trials and Advocating for Patients in Rare Kidney Cancers
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Ivonescimab Shows Dual Inhibition of VEGF and PD-1 Pathways in ccRCC
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic
Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.
Emphasizing The Need to Sustain Kidney Cancer Research Funding at KCRS 2025
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer
Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.
3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.
Personalized Kidney Cancer Vaccines Provide Direction to Immune Therapy
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Expanding Key Kidney Cancer Research Areas Via Institutional Collaboration
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD
Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.
KIM-1 May Predict Higher-Risk Disease in Kidney Cancer
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion
Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.
Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer
Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Early-Stage Kidney Cancer Trial Aims to Restore Anticancer Immunity
A phase 0 trial is seeking to assess the feasibility of aiding anticancer cells with cytokines to restore their function.
Highlighting Beneficial Adjuvant/Neoadjuvant Strategies for Kidney Cancer
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment
A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Data from the DREAMM 7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCC
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.
Applying Clinical Trials to Patient Cases: The Melanoma Landscape
Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.
177Lu-PSMA-617 Trial May Be Efficacious in Advanced PSMA-Expressing ccRCC
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM
Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC
Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.
Research Consortium Aims to Accelerate Progress in Kidney Cancer Management
Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer
A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.
![“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa69f69efca1ade2e100fbb9cdf798d49ea5a0f94-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.")
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.")
